Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
15 December 2022Website:
http://www.gehealthcare.comNext earnings report:
06 February 2025Last dividends:
18 October 2024Next dividends:
N/APrice
regular market | 2 min agoAnalysts recommendations
Institutional Ownership
GEHC Latest News
GE HealthCare's Portrait Mobile solution will enable ongoing monitoring for patients after surgery. It will also offer helpful alerts, improving patient care and reducing the challenges for healthcare professionals.
GEHC and DeepHealth are working together to create AI-powered imaging tools that can improve efficiency and handle large amounts of imaging data while still maintaining accurate diagnoses.
GE Healthcare has obtained FDA approval for its SIGNA MAGNUS 3.0T MRI System, which is designed for head imaging only.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
GE Healthcare Technologies has received a buy rating, aligning with the current consensus from Wall Street and Seeking Alpha analysts. Their recent Q3 results demonstrated growth in several areas, even with challenges from China, and they are essential for providing popular contrast dyes for medical imaging. The stock remains undervalued in various aspects, such as EV/EBITDA and P/E ratios, even though its price is currently above the moving average.
GE HealthCare's separation from GE has created opportunities for each part of the company to grow on its own and target specific markets. In the third quarter, the company reported consistent revenue and profit increases, thanks to improved operations and rising demand for medical technologies. While GE HealthCare is set to benefit from developments in AI and diagnostics, it may experience some short-term challenges in China.
In the third quarter, GEHC saw a drop in revenue from its imaging and ultrasound segments, but this was balanced out by strong results in Pharmaceutical Diagnostics. Overall, profits increased due to improved pricing.
GE HealthCare Technologies Inc. (NASDAQ:GEHC) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 8:30 AM ET. The call will feature company representatives, including Carolynne Borders, Peter Arduini, and Jay Saccaro, along with participants from various financial institutions. Thank you for joining us for this discussion on GE HealthCare's performance.
The financial results for GE HealthCare (GEHC) from the quarter ending in September 2024 provide insight into the company's performance. It may also be helpful to compare some important metrics with Wall Street predictions and figures from the same period last year.
GE HealthCare (GEHC) announced that its profits for the third quarter were higher than anticipated, while its sales were about what analysts had predicted.
What type of business is GE HealthCare Technologies?
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
What sector is GE HealthCare Technologies in?
GE HealthCare Technologies is in the Healthcare sector
What industry is GE HealthCare Technologies in?
GE HealthCare Technologies is in the Health Information Services industry
What country is GE HealthCare Technologies from?
GE HealthCare Technologies is headquartered in United States
When did GE HealthCare Technologies go public?
GE HealthCare Technologies initial public offering (IPO) was on 15 December 2022
What is GE HealthCare Technologies website?
https://www.gehealthcare.com
Is GE HealthCare Technologies in the S&P 500?
Yes, GE HealthCare Technologies is included in the S&P 500 index
Is GE HealthCare Technologies in the NASDAQ 100?
Yes, GE HealthCare Technologies is included in the NASDAQ 100 index
Is GE HealthCare Technologies in the Dow Jones?
No, GE HealthCare Technologies is not included in the Dow Jones index
When was GE HealthCare Technologies the previous earnings report?
No data
When does GE HealthCare Technologies earnings report?
The next expected earnings date for GE HealthCare Technologies is 06 February 2025